JAMES EDGEMOND - 02 Jun 2025 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Role
CFO AND TREASURER
Signature
/s/ John S. Hess, Jr. under Power of Attorney
Issuer symbol
UTHR
Transactions as of
02 Jun 2025
Net transactions value
-$2,496,773
Form type
4
Filing time
03 Jun 2025, 16:30:28 UTC
Previous filing
05 Nov 2024
Next filing
10 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
EDGEMOND JAMES CFO AND TREASURER C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING /s/ John S. Hess, Jr. under Power of Attorney 03 Jun 2025 0001636178

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UTHR Common Stock Options Exercise $1,413,120 +12,000 +148% $117.76 20,118 02 Jun 2025 Direct F1, F2
transaction UTHR Common Stock Sale $847,380 -2,603 -13% $325.54 17,515 02 Jun 2025 Direct F1, F3
transaction UTHR Common Stock Sale $455,896 -1,397 -8% $326.34 16,118 02 Jun 2025 Direct F1, F4
transaction UTHR Common Stock Sale $1,740,929 -5,347 -33% $325.59 10,771 02 Jun 2025 Direct F1, F3
transaction UTHR Common Stock Sale $865,688 -2,653 -25% $326.31 8,118 02 Jun 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UTHR Stock Option Options Exercise $0 -12,000 -11% $0.000000 99,500 02 Jun 2025 Common Stock 12,000 $117.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 6, 2024.
F2 Includes 50 shares of common stock acquired on March 4, 2025 under the United Therapeutics Employee Stock Purchase Plan.
F3 This transaction was executed in multiple trades at prices ranging from $325.00 to $325.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $326.00 to $326.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.